Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds BTIG Downgrades Magenta Therapeutics to Neutral

BTIG Downgrades Magenta Therapeutics to Neutral

BTIG analyst Yun Zhong downgrades Magenta Therapeutics (NASDAQ:MGTA) from Buy to Neutral.

byBenzinga Newsdesk

January 26, 2023

1 minute read

BTIG analyst Yun Zhong downgrades Magenta Therapeutics (NASDAQ:MGTA) from Buy to Neutral.

Related Posts

Read More

Guggenheim Maintains Buy on Phreesia, Raises Price Target to $35

By Benzinga Newsdesk

September 8, 7:40 AM

Guggenheim analyst Jack Wallace maintains Phreesia (NYSE:PHR) with a Buy and raises the price target from $30 to $35.

Read More

News

Foresight Subsidiary, Eye-Net Collaborates With Leading Japanese Insurance Company Aiming To Reduce Accident Rate Through Connected Dashcams

By Benzinga Newsdesk

April 1, 8:30 AM

The insurance company linked Eye-Net and a leading Japanese dashcam company for technology integration and product validationNess Ziona, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- Foresight Autonomous Holdings Ltd.

Read More

Apple Mentioned This Word 23 Times During Tuesday’s Launch — Munster Thinks It Can Boost Mac Growth By Up To 5%

By Shanthi Rexaline

January 18, 2:07 AM

Apple, Inc. (NASDAQ: AAPL) on Tuesday kicked off its launch event for the year with the unveiling of the M2 Pro and M2 Pro Max chips that would be made available for the MacBook Pro and Mac Mini.

Read More

Movers
News

What’s Going On With Reneo Pharmaceuticals Stock Today?

By Dylan Berman

May 13, 1:25 PM

Reneo and Onkure announced Monday that they have entered into a definitive merger agreement to combine the two companies in an all-stock transaction.